Leaflet SAGILIA 1mg tablets


Indicated for: Parkinson's disease

Route of administration: oral

Substance: rasagiline (antiparkinsonian agent)

ATC: N04BD02 (Nervous system | Dopaminergic agents | Monoamine oxidase B inhibitors)

Rasagiline is a medication used to treat Parkinson's disease, a neurodegenerative condition characterized by tremors, rigidity, and movement difficulties. It is a selective monoamine oxidase type B (MAO-B) inhibitor that increases dopamine levels in the brain, thereby alleviating symptoms of the disease.

The medication is taken orally, usually in tablet form, and should be used as directed by your doctor. It is important to follow the prescribed dosage and avoid tyramine-rich foods, such as aged cheeses, to prevent adverse reactions.

Side effects may include headache, dizziness, nausea, or insomnia. In rare cases, severe adverse effects such as high blood pressure or allergic reactions may occur, requiring immediate medical attention.

Patients should inform their doctor about any other medications being used or pre-existing conditions, such as depression or hypertension, to ensure the safe use of rasagiline.

General data about SAGILIA 1mg

  • Substance: rasagiline
  • Date of last drug list: 01-05-2026
  • Commercial code: W62556010
  • Concentration: 1mg
  • Pharmaceutical form: tablets
  • Quantity: 30
  • Product type: generic
  • Price: 89.94 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: MEDOCHEMIE LTD - CIPRU
  • Holder: MEDOCHEMIE LTD - CIPRU
  • Number: 13219/2020/01
  • Shelf life: 3 years

Compensation lists for SAGILIA 1mg Medochemie

G12 (C1) - Parkinson's disease

Price

Copayment

Patient

89.94 RON

88.36 RON

1.58 RON

GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)

Price

Copayment

Patient

89.94 RON

88.36 RON

1.58 RON